title: Palliative Radiation Therapy for Advanced Head and Neck Carcinomas: A Phase 2 Study.
abstract: Incurable head and neck cancer is hard to manage with usual palliative care. Radiation therapy (RT) in this setting is sometimes omitted because there is an apprehension that the side effects in the head and neck region might counterbalance the benefits. The objective of this phase 2 study was to evaluate whether highly conformal RT could improve the therapeutic ratio with this comprehensive Quality of Life (QOL) and toxicity evaluation.
  
  
  
  Patients from 2 academic centers, deemed unfit for radical treatment because of their poor medical condition or advanced cancer stage by an experienced tumor board, were offered 25 Gy in 5 daily intensity modulated RT fractions over 1 week to the symptomatic tumor volume. QOL was evaluated with the European Organization for Research and Treatment of Cancer QLQ-C15-PAL and QLQ-H&N35 questionnaires, and toxicities with the Common Terminology Criteria for Adverse Events version 4.0. Survival and time to tumor progression were calculated with the Kaplan-Meier method.
  
  
  
  Thirty-two patients were recruited, of whom 66% had at least T4, N3, or M1 disease. The QOL questionnaires completion rate was 86%. Eighty-eight percent of patients received the planned dose. The median overall survival and progression-free survival times were, respectively, 6.5 and 3.2 months. No grade 4 or 5 toxicity was seen. Only 13% of patients had any grade 3 toxicities, and 17% of patients reported no toxicity at all. The QOL was equal or improved, and head and neck symptoms remained equal to or lower than the baseline values for most patients at up to 6 months. Eighty-five percent of patients would have chosen to receive this RT regimen again when asked.
  
  
  
  This palliative RT regimen was highly tolerable and effective in preserving or improving self-reported QOL in most patients for up to 6 months, which corresponds to this population's median overall survival. Given the minimal side effects, intensification could be considered to achieve longer locoregional control.
authors.affiliation: Radiation Oncology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada. Electronic address: bfortin.hmr@ssss.gouv.qc.ca.
authors.forename: Bernard
authors.initials: B
authors.lastname: Fortin
authors.affiliation: Radiation Oncology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
authors.forename: Nader
authors.initials: N
authors.lastname: Khaouam
authors.affiliation: Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Edith
authors.initials: E
authors.lastname: Filion
authors.affiliation: Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Phuc Felix
authors.initials: PF
authors.lastname: Nguyen-Tan
authors.affiliation: Radiation Oncology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
authors.forename: Alexis
authors.initials: A
authors.lastname: Bujold
authors.affiliation: Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
authors.forename: Louise
authors.initials: L
authors.lastname: Lambert
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000523:psychology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011788:Quality of Life; D020266:Radiotherapy, Conformal / Q000009:adverse effects